Isoprene is a normal constituent of human breath and may be derived fr
om the cholesterol synthetic pathway. Acute and chronic lovastatin and
a cholesterol-supplemented diet were used to determine whether a mech
anistic link exists between isoprene and cholesterol biosynthesis in v
ivo in humans. The acute effects of lovastatin, a competitive inhibito
r of the rate-limiting step of cholesterol biosynthesis, on breath iso
prene excretion was determined by administering a single 20, 40 or 80
mg dose of this drug to five healthy male subjects at 8 pm. and measur
ing their breath isoprene levels every 4 h for one 24 h cycle before a
nd after treatment. When compared to the baseline cycle, all three dos
es of lovastatin significantly reduced breath isoprene levels at 6 and
10 h post-drug treatment. Chronic lovastatin therapy (40 mg b.i.d. fo
r 6 wk) reduced 6 a.m. breath isoprene levels (time of maximum baselin
e value) by 27 +/- 9% (SEM) and cholesterol synthesis measured in fres
hly isolated mononuclear leukocytes (ML) by 12 +/- 6%. A cholesterol-s
upplemented diet (1070 mg, total) ingested for 6 wk reduced breath iso
prene excretion and ML sterol synthesis by 16 +/- 5 and 19 +/- 4%, res
pectively. The parallel decreases in isoprene excretion and cholestero
l synthesis caused by these pharmacologic and dietary means suggest th
at breath isoprene is derived from the cholesterol synthesis pathway.